{"meta":{"status":200,"messages":[],"pagination":{"max":1,"offset":0,"count":1,"total":1,"pageNum":1,"totalPages":1,"sort":null,"currentUrl":"https://api.digitalmedia.hhs.gov/api/v2/resources/media.json?offset=0&max=1&ignoreHiddenMedia=1&format=json&id=1760","nextUrl":null,"previousUrl":null}},"results":[{"content":"\n
\n \n

Obesity and Cancer

\n
\n \n
\n
\n

What is obesity?

\n
\n
\n

Obesity is a disease in which a person has an unhealthy amount and/or distribution of body fat (1). Compared with people of healthy weight, those with overweight or obesity are at greater risk for many diseases, including diabetes, high blood pressure, cardiovascular disease, stroke, and at least 13 types of cancer, as well as having an elevated risk of death from all causes (2\u20135).

\n

To determine someone\u2019s level of body fat, doctors commonly use a measure known as the body mass index (BMI). BMI is calculated by dividing a person\u2019s weight (in kilograms) by their height (in meters) squared (commonly expressed as kg/m2). BMI is not a direct measure of body fat, but it provides a more accurate assessment of obesity than weight alone. It is a useful estimate of body fatness in populations but cannot be used on its own to  indicate obesity-related disease risks in individuals (6).

\n

The National Heart Lung and Blood Institute has a BMI calculator for adults. The standard weight categories based on BMI for adults ages 20 years or older are:

\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
BMI in kg/m2 Weight category
Below 18.5Underweight
18.5 to 24.9Healthy
25.0 to 29.9Overweight
30.0 to 39.9Obese
40.0 or higherSeverely obese
\n
\n

The Centers for Disease Control and Prevention (CDC) has a BMI percentile calculator for children and teens. Overweight and obesity for people younger than 20 years old, whose BMI can change significantly as they grow, are based on CDC\u2019s BMI-for-age growth charts. 

\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
BMIWeight category
BMI-for-age below the sex-specific 5th percentile Underweight
BMI-for-age at or above the sex-specific 5th percentile, but less than the 85th percentileHealthy
BMI-for-age at or above the sex-specific 85th percentile, but less than the 95th percentile Overweight
BMI-for-age at or above the sex-specific 95th percentileObese
BMI-for-age at or above 120% of the sex-specific 95th percentile*Severe obesity
*Based on recommendations from experts (7) 
\n
\n

Measurements that reflect the distribution of body fat are sometimes used along with BMI as indicators of obesity and disease risks. These measurements include waist circumference, waist-to-hip ratio (the waist circumference divided by the hip circumference), waist-to-height ratio, and fat distribution as measured by dual energy X-ray absorptiometry (DXA or DEXA), imaging with CT or PET, or measurements of body shape (8).

\n

These measures are used because the distribution of fat is increasingly understood to be relevant to disease risks. In particular, visceral fat\u2014fat that surrounds internal organs\u2014seems to be more dangerous, in terms of disease risks, than overall fat or subcutaneous fat (the layer just under the skin).

\n
\n
\n
\n
\n

How common are overweight and obesity?

\n
\n
\n

Obesity has become more common in the United States in recent years\u2014so common that it is sometimes referred to as an obesity epidemic. According to the CDC (9), 

\n
    \n
  • In 2011, 27.4% of adults ages 18 or older had obesity.
    • \n
  • In 2023, 32.8% of adults ages 18 or older had obesity. 
    • \n
\n

The prevalence of obesity in the United States differs among racial and ethnic groups (9). In 2023, according to the CDC, the proportions of adults ages 18 years or older with obesity were:

\n
    \n
  • Non-Hispanic Black, 42.0%
    • \n
  • American Indian/Alaska Native, 39.6%
    • \n
  • Hawaiian/Pacific Islander, 31.8%
    • \n
  • Hispanic, 35.1%
    • \n
  • Non-Hispanic White, 32.2%
    • \n
  • Asian, 13.4% 
    • \n
\n

An analysis of changes in the prevalence of overweight and obesity combined in the United States from 1990 to 2021 found that it has increased in all age groups examined (10). For example,

\n

Among adults ages 25 or older

\n
    \n
  • 49.1% of females and 60.5% of males had overweight or obesity in 1990
    • \n
  • 72.6% of females and 75.9% of males had overweight or obesity in 2021
    • \n
\n

Among adolescents ages 15\u201324 years

\n
    \n
  • 26.0% of females and 31.4% of males had overweight or obesity in 1990
    • \n
  • 50.8% of females and 46.7% of males had overweight or obesity in 2021
    • \n
\n

Among children ages 10\u201314 years

\n
    \n
  • 22.3% of females and 23% of males had overweight or obesity in 1990
    • \n
  • 41.7% of females and 41.9% of males had overweight or obesity in 2021
    • \n
\n
\n
\n
\n
\n

What is known about the relationship between overweight and obesity and cancer?

\n
\n
\n

The best evidence linking overweight and obesity to cancer risk comes from large cohort studies, a type of observational study. 

\n

An International Agency for Research on Cancer (IARC) Working Group concluded, based on a review of more than 1000 such studies, that there is consistent evidence that higher amounts of body fat are associated with an increased risk of a number of cancers. Cancers that have been found to be linked to obesity or overweight include

\n
\n
View and Print Infographic\" data-embed-button=\"cgov_infographic_button\" data-entity-embed-display=\"view_mode:media.infographic_display_article_medium\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"65770b93-95a7-4cb2-904e-a14f7cd3295f\" data-langcode=\"en\"> \n
\n
\n
\n \"Diagram \n
\n \n
\n
\n
\n
\n

 

\n \n

 

\n

 

\n

 

\n

The risk increases associated with obesity are highest for endometrial and esophageal cancers.

\n
    \n
  • For type 1 endometrial cancers (those linked to excess estrogen), people with severe obesity have about seven times the risk and those with overweight or obesity have two to four times the risk, compared with people of healthy weight.
    • \n
  • For esophageal cancer, those with severe obesity have nearly five times the risk and those with obesity have more than twice the risk, compared with people of healthy weight.
    • \n
  • For the other obesity-associated cancer types, risk increases in people with obesity range from about a 10% increase in risk to a doubling of risk. 
    • \n
\n

A recent study of more than 2 million people in Spain who were followed for a median of 9 years found evidence that overweight and obesity are linked to 18 cancers, including some not yet considered to be related to obesity (30). 

\n

People who have a higher BMI at the time of cancer diagnosis have higher risks of developing a second primary cancer (a cancer not related to the first cancer) in the future (31\u201334).

\n
\n
\n
\n
\n

How might obesity increase the risk of cancer?

\n
\n
\n

Several possible mechanisms have been suggested to explain how obesity might increase the risks of some cancers (35, 36).

\n
    \n
  • Fat tissue (also called adipose tissue) produces excess amounts of estrogen, which is known to cause cancer. High levels of estrogen have been associated with increased risks of breast, endometrial, ovarian, and some other cancers.
    • \n
  • People with obesity often have increased blood levels of insulin and insulin-like growth factor-1 (IGF-1). High levels of insulin, a condition known as hyperinsulinemia, is due to insulin resistance and precedes the development of type 2 diabetes, another known cancer risk factor. High levels of insulin and IGF-1 are associated with increased risks of colorectal, thyroid, breast, prostate, ovarian, and endometrial cancers (37, 38).
    • \n
  • People with obesity often have chronic inflammation, which directly promotes tumor growth by several mechanisms (39).
    • \n
  • Fat cells produce hormones called adipokines, which can stimulate or inhibit cell growth (40). For example, the blood level of an adipokine called leptin increases with increasing body fat, and high levels of leptin can promote aberrant cell proliferation. Another adipokine, adiponectin, which may have antiproliferative effects that protect against tumor growth, is less abundant in people with obesity than in people with a healthy weight.
    • \n
  • Fat cells may also have direct and indirect effects on other cell growth and metabolic regulators. These include mammalian target of rapamycin (mTOR) and AMP-activated protein kinase, both of which are involved in regulating autophagy, which when impaired can lead to cancer (41).
    • \n
\n

Other possible mechanisms by which obesity could affect cancer risk include a mechanical effect on the lower esophageal sphincter that induces gastroesophageal reflux disease (a risk factor for esophageal adenocarcinoma); impaired tumor immunity; and changes in the structure of the tissue that surrounds developing tumors (42, 43).

\n

In addition to its biological effects, obesity can lead to challenges in screening and management. For example, women with overweight or obesity have a higher risk of cervical cancer than women of healthy weight, likely because cervical cancer screening is less effective in these individuals (44).

\n
\n
\n
\n
\n

How many cancer cases may be due to excess body weight?

\n
\n
\n

A study that used nationally representative data on cancer incidence and mortality and risk factor prevalence estimated that in 2019 among people ages 30 and older in the United States, about 43,720 new cancer cases in men (4.8%) and 92,200 new cancer cases in women (10.6%) were due to excess body weight (overweight and obesity) (45). The percentage of cases attributed to excess body weight varied widely across cancer types and was as high as 34.9% for liver cancer and 53.1% for endometrial cancer in women and 37.1% for gallbladder cancer and 37.8% for esophageal adenocarcinoma in men.

\n

A 2024 study examined whether the increasing incidence of early-onset cancers over the period 2000 to 2012 worldwide could be explained by increasing rates of obesity among young adults over this period (46). Six of nine obesity-related cancers increased in incidence among young adults during this period, and for four of these cancers (colon, rectal, pancreatic, and kidney), this rise was associated with increases in body weight. This finding suggests a possible link between the obesity epidemic and the rising incidence in these early-onset cancers worldwide (46).  Obesity has also been linked to increased risks of early-onset breast cancer in Black women (47, 48).

\n
\n
\n
\n
\n

Does losing weight lower the risk of cancer?

\n
\n
\n

Most of the data about whether losing weight reduces cancer risk comes from observational studies such as cohort  and case\u2013control studies. Randomized controlled studies of weight loss diets have been done, but they sometimes failed to produce substantial weight change, and did not appear to reduce cancer risk (49). Observational studies of weight loss and cancer risk should be interpreted with caution because other differences between people who lose weight and those who don\u2019t may account for their different cancer risks.

\n

Some of these studies have found lower risks of breast, endometrial, colon, and prostate cancers among people with obesity who had lost weight. For example, in one large prospective study of postmenopausal women, those who intentionally lost more than 5% of body weight had a lower risk of obesity-related cancers, especially endometrial cancer (50).

\n

And among postmenopausal women in the Women\u2019s Health Initiative Observational Study, those who lost at least 5% of their body weight during study follow up had a lower risk of invasive breast cancer than those whose weight was stable (51). Also, results of a study that pooled data from 10 cohorts suggested that sustained weight loss was associated with lower breast cancer risk among women 50 years and older (52).

\n

Weight loss through bariatric surgery (surgery performed on the stomach or intestines to provide maximum and sustained weight loss) has also been found to be associated with reduced cancer risks (53). Studies have found that people with obesity, particularly women, who had bariatric surgery had lower risks of cancer overall (54); of hormone-related cancers, such as breast (55), endometrial, and prostate cancers (56); and of obesity-related cancers, such as postmenopausal breast cancer, endometrial cancer, esophageal, gastric, and colon cancer (57\u201359).

\n

Weight loss through medications approved to treat obesity (including the GLP-1 receptor agonists tirzepatide, semaglutide, and liraglutide) has also been found to be associated with reduced risks of some obesity-related cancers. For example, in a large nationwide retrospective cohort study, people with type 2 diabetes with no prior diagnosis of an obesity-related cancer who were prescribed GLP-1 receptor agonists had lower risks of 10 of 13 obesity-related cancers, including esophageal, colorectal, kidney, pancreatic, gallbladder, ovarian, endometrial, and liver cancers as well as meningioma and multiple myeloma (60). However, a meta-analysis of randomized controlled trials with an average of 3 years of follow-up per participant found no association between GLP-1 receptor agonists and the risk of any gastrointestinal cancer, including colorectal, pancreatic, liver, or gallbladder cancers (61).

\n
\n
\n
\n
\n

How does obesity affect cancer survivors?

\n
\n
\n

Most of the evidence about obesity in cancer survivors comes from people who were diagnosed with breast, prostate, or colorectal cancer. Research indicates that obesity may worsen several aspects of cancer survivorship, including quality of life, cancer recurrence, cancer progression, prognosis (survival), and risk of certain second primary cancers (31, 32, 34, 62, 63).

\n

For example, obesity is associated with increased risks of treatment-related lymphedema in breast cancer survivors (64) and of incontinence in prostate cancer survivors treated with radical prostatectomy (65). In a large clinical trial of patients with stage II and stage III rectal cancer, those with a higher baseline BMI (particularly men) had an increased risk of local recurrence (66). In a large analysis that included 1.5 million people with multiple myeloma, those with the highest levels of obesity were 50% more likely to die from their disease than those at healthy weight (67).

\n
\n
\n
\n
\n

Is weight loss after a cancer diagnosis beneficial for people with overweight or obesity?

\n
\n
\n

Most studies of how weight loss affects outcomes in people with cancer have focused on breast cancer. Several randomized clinical trials in breast cancer survivors have reported that weight loss interventions resulted in both weight loss and beneficial changes in biomarkers that have been linked to the association between obesity and prognosis (68, 69).

\n

However, there is little evidence about whether weight loss reduces the risk of breast cancer recurrence or death (70). The NCI-sponsored Breast Cancer WEight Loss (BWEL) Study, an ongoing randomized phase 3 trial, is examining whether participating in a weight loss program after breast cancer diagnosis lowers the risk of recurrence among overweight and obese women (71).

\n
\n
\n
\n
\n

What research is being done on obesity and cancer?

\n
\n
\n

In addition to studies of the mechanisms by which obesity influences cancer risk, researchers are exploring whether associations vary by race or ethnicity (72). Also, researchers are investigating whether different cutoffs for overweight and obesity should be used for different racial/ethnic groups. For example, the World Health Organization (WHO) has suggested the alternate thresholds of 23.0 and 27.5 kg/m2 for overweight and obesity for people of Asian ancestry (73).

\n

The NCI Cohort Consortium is an extramural\u2013intramural partnership that combines more than 50 prospective cohort studies from around the world with more than 7 million participants. The studies are gathering information on diet and physical activity and body mass index, waist circumference, and other measures of adiposity from each cohort. The large size of the consortium will allow researchers to get a better sense of how obesity-related factors relate to less common cancers, such as cancers of the thyroid, gallbladder, head and neck, and kidney.

\n

Another area of study is focused on developing more precise and effective interventions to prevent weight gain and weight regain after weight loss. This area of research includes two NIH-based initiatives\u2014the Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures (74) and the Trans-NIH Consortium of Randomized Controlled Trials of Lifestyle Weight Loss Interventions (75)\u2014both of which aim to identify predictors of successful weight loss and maintenance and to incorporate information on genetic, psychosocial, behavioral, biological, and environmental factors into predictive profiles to enable more precise and, ultimately, more effective weight loss interventions.

\n

NCI supports research on obesity and cancer risk through a variety of activities, including large cooperative initiatives, web and data resources, epidemiologic and basic science studies, and dissemination and implementation resources. For example, the Transdisciplinary Research on Energetics and Cancer (TREC) initiative supports ongoing training workshops for postdocs and early career investigators to enhance the ability to produce innovative and impactful transdisciplinary research in energetics and cancer and clinical care. The NCI Metabolic Dysregulation and Cancer Risk Program supports research into the biological mechanisms underlying the development of obesity-related cancers and identifies potential markers to enhance cancer risk prediction, improve screening for high-risk individuals, and identify targets for preventive and therapeutic interventions of obesity-related cancers.

\n

The Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors consortium is a collaborative NCI-funded research program whose goal is to improve the future of cancer care through exercise and dietary approaches.

\n
\n
\n
\n
\n
\n
\n
\n
\n

Selected References

\n
    \n

  1. Garvey WT, Mechanick JI. Proposal for a scientifically correct and medically actionable disease classification system (ICD) for obesity. Obesity (Silver Spring) 2020; 28(3):484\u2013492.

    [PubMed Abstract]
    2. \n

  2. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. New England Journal of Medicine 2010; 363(23):2211\u20132119.

    [PubMed Abstract]
    3. \n

  3. Kitahara CM, Flint AJ, Berrington de Gonzalez A, et al. Association between class III obesity (BMI of 40\u201359 kg/m2) and mortality: A pooled analysis of 20 prospective studies. PLoS Medicine 2014; 11(7):e1001673.

    [PubMed Abstract]
    4. \n

  4. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. New England Journal of Medicine 2006; 355(8):763\u2013778.

    [PubMed Abstract]
    5. \n

  5. Cohen SS, Park Y, Signorello LB, et al. A pooled analysis of body mass index and mortality among African Americans. PLoS One 2014; 9(11):e111980.

    [PubMed Abstract]
    6. \n

  6. Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: What is the path forward? Current Obesity Reports 2024; 13(3):584\u2013595. doi: 10.1007/s13679-024-00580-1

    7. \n

  7. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2\u201319 years: United States, 1963\u20131965 through 2017\u20132018. NCHS Health E-Stats. 2020.

    8. \n

  8. Zhang X, Ma N, Lin Q, et al. Body roundness index and all-cause mortality among US adults. JAMA Network Open 2024; 7(6):e2415051.

    [PubMed Abstract]
    9. \n

  9. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity: Data, Trend and Maps [online]. [accessed Dec 26, 2024]. URL: https://www.cdc.gov/nccdphp/dnpao/data-trends-maps/index.html

    10. \n

  10. GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050. Lancet 2024; 404(10469):2278\u20132298.

    [PubMed Abstract]
    11. \n

  11. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: Have they different risk factors? Journal of Clinical Oncology 2013; 31(20):2607\u20132618.

    [PubMed Abstract]
    12. \n

  12. Dougan MM, Hankinson SE, Vivo ID, et al. Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. International Journal of Cancer 2015; 137(3):625\u2013637.

    [PubMed Abstract]
    13. \n

  13. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: A pooled analysis from the International BEACON Consortium. International Journal of Epidemiology 2012; 41(6):1706\u20131718.

    [PubMed Abstract]
    14. \n

  14. Chen Y, Liu L, Wang X, et al. Body mass index and risk of gastric cancer: A meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(8):1395\u20131408.

    [PubMed Abstract]
    15. \n

  15. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. European Journal of Cancer 2012; 48(14):2137\u20132145.

    [PubMed Abstract]
    16. \n

  16. Campbell PT, Newton CC, Freedman ND, et al. Body mass index, waist circumference, diabetes, and risk of liver cancer for U.S. adults. Cancer Research 2016; 76(20):6076\u20136083.

    [PubMed Abstract]
    17. \n

  17. Wang F, Xu Y. Body mass index and risk of renal cell cancer: A dose-response meta-analysis of published cohort studies. International Journal of Cancer 2014; 135(7):1673\u20131686.

    [PubMed Abstract]
    18. \n

  18. Sanfilippo KM, McTigue KM, Fidler CJ, et al. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension 2014; 63(5):934\u2013941.

    [PubMed Abstract]
    19. \n

  19. Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. European Journal of Cancer 2011; 47(11):1606\u20131615.

    [PubMed Abstract]
    20. \n

  20. Niedermaier T, Behrens G, Schmid D, et al. Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology 2015; 85(15):1342\u20131350.

    [PubMed Abstract]
    21. \n

  21. Genkinger JM, Spiegelman D, Anderson KE, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. International Journal of Cancer 2011; 129(7):1708\u20131717.

    [PubMed Abstract]
    22. \n

  22. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: A systematic review of prospective studies. PLoS One 2013; 8(1):e53916.

    [PubMed Abstract]
    23. \n

  23. World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and gallbladder cancer. Available at https://www.wcrf.org/wp-content/uploads/2021/02/gallbladder-cancer-report.pdf.

    24. \n

  24. Li L, Gan Y, Li W, Wu C, Lu Z. Overweight, obesity and the risk of gallbladder and extrahepatic bile duct cancers: A meta-analysis of observational studies. Obesity (Silver Spring) 2016; 24(8):1786\u20131802.

    [PubMed Abstract]
    25. \n

  25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371(9612):569\u2013578.

    [PubMed Abstract]
    26. \n

  26. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiologic Reviews 2014; 36:114\u2013136.

    [PubMed Abstract]
    27. \n

  27. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Medicine 2012; 9(4):e1001200.

    [PubMed Abstract]
    28. \n

  28. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology 2016; 34(24):2888\u20132898.

    [PubMed Abstract]
    29. \n

  29. Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995\u20132015). Journal of the National Cancer Institute 2020; 112(8):810\u2013817.

    [PubMed Abstract]
    30. \n

  30. Recalde M, Pistillo A, Davila-Batista V, et al. Longitudinal body mass index and cancer risk: A cohort study of 2.6 million Catalan adults. Nature Communications 2023; 14(1):3816.

    [PubMed Abstract]
    31. \n

  31. Bodelon C, Sung H, Mitchell EL, et al. Excess body weight and the risk of second primary cancers among cancer survivors. JAMA Network Open 2024; 7(9):e2433132.

    [PubMed Abstract]
    32. \n

  32. Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. JAMA 2020; 324(24):2521\u20132535.

    [PubMed Abstract]
    33. \n

  33. Gibson TM, Park Y, Robien K, et al. Body mass index and risk of second obesity-associated cancers after colorectal cancer: A pooled analysis of prospective cohort studies. Journal of Clinical Oncology 2014; 32(35):4004\u20134011.

    [PubMed Abstract]
    34. \n

  34. Feigelson HS, Bodelon C, Powers JD, et al. Body mass index and risk of second cancer among women with breast cancer. Journal of the National Cancer Institute 2021; 113(9):1156\u20131160.

    [PubMed Abstract]
    35. \n

  35. Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: Epidemiologic evidence and biologic mechanisms. Molecular Oncology 2021; 15(3):790\u2013800.

    [PubMed Abstract]
    36. \n

  36. Liu XZ, Pedersen L, Halberg N. Cellular mechanisms linking cancers to obesity. Cell Stress 2021; 5(5):55\u201372.

    [PubMed Abstract]
    37. \n

  37. Knuppel A, Fensom GK, Watts EL, et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: Prospective analyses in UK Biobank. Cancer Research 2020; 80(18):4014\u20134021

    [PubMed Abstract]
    38. \n

  38. Leitner BP, Siebel S, Akingbesote ND, Zhang X, Perry RJ. Insulin and cancer: A tangled web. The Biochemical Journal 2022; 479(5):583\u2013607.

    [PubMed Abstract]
    39. \n

  39. Greten FR, Grivennikov SI. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 2019; 51(1):27\u201341.

    [PubMed Abstract]
    40. \n

  40. Kim JW, Kim JH, Lee YJ. The role of adipokines in tumor progression and its association with obesity. Biomedicines 2024; 12(1):97.

    [PubMed Abstract]
    41. \n

  41. Behrooz AB, Cordani M, Fiore A, et al. The obesity-autophagy-cancer axis: Mechanistic insights and therapeutic perspectives. Seminars in Cancer Biology 2024; 99:24\u201344.

    [PubMed Abstract]
    42. \n

  42. Seo BR, Bhardwaj P, Choi S. Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Science Translational Medicine 2015; 7(301):301ra130.

    [PubMed Abstract]
    43. \n

  43. Derakhshan MH, Robertson EV, Fletcher J, et al. Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. Gut 2012; 61(3):337\u2013343.

    [PubMed Abstract]
    44. \n

  44. Clarke MA, Fetterman B, Cheung LC, et al. Epidemiologic evidence that excess body weight increases risk of cervical cancer by decreased detection of precancer. Journal of Clinical Oncology 2018; 36(12):1184\u20131191.

    [PubMed Abstract]
    45. \n

  45. Islami F, Marlow EC, Thomson B, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA: A  Cancer Journal for Clinicians 2024; 74(5):405\u2013432.

    [PubMed Abstract]
    46. \n

  46. Chen J, Dalerba P, Terry MB, Yang W. Global obesity epidemic and rising incidence of early-onset cancers. Journal of Global Health 2024; 14:04205.

    [PubMed Abstract]
    47. \n

  47. Sudan SK, Sharma A, Vikramdeo KS, et al. Obesity and early-onset breast cancer and specific molecular subtype diagnosis in Black and White women: NIMHD Social Epigenomics Program. JAMA Network Open 2024; 7(7):e2421846.

    [PubMed Abstract]
    48. \n

  48. Micaily I, Hackbart H, Butryn M, Abu-Khalaf MM. Obesity in early onset breast cancer in African American patients. The Breast Journal 2021; 27(7):603\u2013607.

    [PubMed Abstract]
    49. \n

  49. Sauter ER, Butera G, Agurs-Collins T. Long-term randomized controlled trials of diet intervention reports and their impact on cancer: A systematic review. Cancers (Basel) 2024; 16(19):3296.

    [PubMed Abstract]
    50. \n

  50. Luo J, Hendryx M, Manson JE, et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectrum 2019; 3(4):pkz054.

    [PubMed Abstract]
    51. \n

  51. Chlebowski RT, Luo J, Anderson GL, et al. Weight loss and breast cancer incidence in postmenopausal women. Cancer 2019; 125(2):205\u2013212.

    [PubMed Abstract]
    52. \n

  52. Teras LR, Patel AV, Wang M, et al. Sustained weight loss and risk of breast cancer in women 50 years and older: A pooled analysis of prospective data. Journal of the National Cancer Institute 2020; 112(9):929\u2013937.

    [PubMed Abstract]
    53. \n

  53. Madar LO, Goldberg N, Netz U, et al. Association between metabolic and bariatric surgery and malignancy: A systematic review, meta-analysis, trends, and conclusions. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery 2024:S1550\u20137289(24)00866-9.

    [PubMed Abstract]
    54. \n

  54. Tee MC, Cao Y, Warnock GL, Hu FB, Chavarro JE. Effect of bariatric surgery on oncologic outcomes: A systematic review and meta-analysis. Surgical Endoscopy 2013; 27(12):4449\u20134456.

    [PubMed Abstract]
    55. \n

  55. Kristensson FM, Andersson-Assarsson JC, Peltonen M, et al. Breast cancer risk after bariatric surgery and influence of insulin levels: A nonrandomized controlled trial. JAMA Surgery 2024; 159(8):856\u2013863.

    [PubMed Abstract]
    56. \n

  56. Mackenzie H, Markar SR, Askari A, et al. Obesity surgery and risk of cancer. British Journal of Surgery 2018; 105(12):1650\u20131657.

    [PubMed Abstract]
    57. \n

  57. Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Annals of Surgery 2019; 269(1):95\u2013101.

    [PubMed Abstract]
    58. \n

  58. Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer Risk and mortality in adults with obesity. JAMA 2022; 327(24):2423\u20132433.

    [PubMed Abstract]
    59. \n

  59. Lazzati A, Poghosyan T, Touati M, Collet D, Gronnier C. Risk of esophageal and gastric cancer after bariatric surgery. JAMA Surgery 2023; 158(3):264\u2013271.

    [PubMed Abstract]
    60. \n

  60. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Network Open 2024; 7(7):e2421305.

    [PubMed Abstract]
    61. \n

  61. Figlioli G, Piovani D, Peppas S, et al. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 2024; 208:107401.

    [PubMed Abstract]
    62. \n

  62. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 2003; 348(17):1625\u20131638.

    [PubMed Abstract]
    63. \n

  63. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. Journal of the National Cancer Institute 2013; 105(18):1344\u20131354.

    [PubMed Abstract]
    64. \n

  64. Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: A review. Journal of Clinical Oncology 2012; 30(30):3726\u20133733.

    [PubMed Abstract]
    65. \n

  65. Gacci M, Sebastianelli A, Salvi M, et al. Role of abdominal obesity for functional outcomes and complications in men treated with radical prostatectomy for prostate cancer: Results of the Multicenter Italian Report on Radical Prostatectomy (MIRROR) study. Scandinavian Journal of Urology 2014; 48(2):138\u2013145.

    [PubMed Abstract]
    66. \n

  66. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. Journal of Clinical Oncology 2004; 22(4):648\u2013657.

    [PubMed Abstract]
    67. \n

  67. Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: A pooled analysis of 20 prospective studies. British Journal of Haematology 2014; 166(5):667\u2013676.

    [PubMed Abstract]
    68. \n

  68. Goodwin PJ, Segal RJ, Vallis M, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: The LISA trial. Journal of Clinical Oncology 2014; 32(21):2231\u20132239.

    [PubMed Abstract]
    69. \n

  69. Harrigan M, Cartmel B, Loftfield E, et al. Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. Journal of Clinical Oncology 2016; 34(7):669\u2013676.

    [PubMed Abstract]
    70. \n

  70. Goodwin PJ. Obesity and breast cancer outcomes: How much evidence is needed to change practice? Journal of Clinical Oncology 2016; 34(7):646\u2013648. Epub 2015 Dec 28. doi: 10.1200/JCO.2015.64.7503.

    71. \n

  71. Delahanty LM, Wadden TA, Goodwin PJ, et al. The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. Obesity (Silver Spring) 2022; 30(1):28-38.

    [PubMed Abstract]
    72. \n

  72. Bandera EV, Alfano CM, Qin B, et al. Harnessing nutrition and physical activity for breast cancer prevention and control to reduce racial/ethnic cancer health disparities. American Society of Clinical Oncology educational book 2021; 41:1\u201317.

    [PubMed Abstract]
    73. \n

  73. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363(9403):157\u2013163.

    [PubMed Abstract]
    74. \n

  74. MacLean PS, Rothman AJ, Nicastro HL, et al. The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) core measures project: Rationale and approach. Obesity (Silver Spring) 2018; 26 Suppl 2(Suppl 2):S6\u2013S15.

    [PubMed Abstract]
    75. \n

  75. Bray MS, Loos RJ, McCaffery JM, et al. NIH working group report-using genomic information to guide weight management: From universal to precision treatment. Obesity (Silver Spring) 2016; 24(1):14\u201322.

    [PubMed Abstract]
    76. \n
\n
\n
\n \n
\n

Posted:

\n

Updated:

\n

Reviewed:

\n
\n This content is provided by the National Cancer Institute (www.cancer.gov) \n
\n
\n \n
Syndicated Content Details:
Source URL: https://www.cancer.gov/node/14822/syndication
Source Agency: National Cancer Institute (NCI)
Captured Date: 2014-01-14 22:15:07.0
","description":"A fact sheet that summarizes the evidence linking overweight and obesity to the risk of various cancers and to cancer survivorship.","id":1760,"mediaType":"Html","name":"Obesity and Cancer","sourceUrl":"https://www.cancer.gov/node/14822/syndication"}]}